Research finds that even short gaps in treatment with a GLP-1 can drive up risks of heart attack, stroke and death in patients with Type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results